Cochrane · systematic review · CD007783
Lamotrigine add‐on therapy for drug‐resistant generalised tonic‐clonic seizures
Bresnahan, R, Panebianco, M, Marson, AG · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 75%Low 1 · 25%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Add‐on lamotrigine compared to placebo for drug‐resistant generalised tonic‐clonic seizures
Population: people with drug‐resistant generalised tonic‐clonic seizures
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency Add‐on lamotrigine vs placebo | RR 1.88 [1.43, 2.45] | 2 studies · 270 participants | Low Downgraded: risk of bias, imprecision |
Seizure freedom (i.e. total cessation of seizure activity) Add‐on lamotrigine vs placebo | RR 1.55 [0.89, 2.72] | 2 studies · 270 participants | Very low Downgraded: risk of bias, imprecision |
Treatment withdrawal Add‐on lamotrigine vs placebo | RR 1.2 [0.72, 1.99] | 2 studies · 270 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects Add‐on lamotrigine vs placebo | RR 0.91 [0.29, 2.86] | 2 studies · 270 participants | Very low Downgraded: risk of bias, imprecision |